Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Cliona Rooney
Professor at Baylor College of Medicine


I received my PhD in viral immunology from Cambridge University in 1981, followed by postdoctoral fellowships at the Universities of Bristol and Birmingham with Alan Rickinson, and at Yale (USA) with George Miller. In 1990, I joined the faculty at St Jude Children’s Research Hospital, where I developed my interests in immunotherapy and used Epstein-Barr virus-specific T-cells to treat EBV positive malignancies. At Baylor College of Medicine, we expanded these therapies to prevent and treat other viral infections of stem cell transplant (HSCT) recipients, to target HPV-positive malignancies and to use virus-specific T-cells expressing chimeric antigen receptors (CARs) targeting non-viral tumor antigens. The anti-tumor activity of CAR-VSTs can then be boosted by endogenous viruses, viral vaccines or oncolytic viruses . Current interests are in enhancing the expansion and persistence of tumor-specific T-cells using biological response modifiers

Cliona Rooney's Network

Agenda Sessions

  • Improving the in vivo persistence and function of tumor-specific T-cells

    , 1:45pm